given the amount of new information about FTO coming in, coupled with the CoH, I'd speculate the same thing.
I would think a big pharma would be wanting to acquire bisantrene at a lower premium than if we had finished our phase II. That risk in my opinion, is quite real as Dr T. has mentioned it being out of his hands. Us as shareholders need to be aware that any big pharma will want to buy us at the lowest price possible.
BMS and Merck have opdivo and keytruda, opdivo is currently behind keytruda. If they can use bisantrene to catapult them above keytruda, something like this would be on their radar(I would think).
See you no 100$, page-9
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |